1326. Mupirocin Resistance in Staphylococcus aureus in Pediatric Patients for Ten Years. (15th December 2022)
- Record Type:
- Journal Article
- Title:
- 1326. Mupirocin Resistance in Staphylococcus aureus in Pediatric Patients for Ten Years. (15th December 2022)
- Main Title:
- 1326. Mupirocin Resistance in Staphylococcus aureus in Pediatric Patients for Ten Years
- Authors:
- Park, Hwanhee
Kim, Doo Ri
Kim, Kyung-Ran
Kim, Jong Min
Huh, Hee Jae
Lee, Nam Yong
Kim, Yae-Jean - Abstract:
- Abstract: Background: Mupirocin has been recommended for decolonization in methicillin-resistant Staphylococcus aureus (MRSA) carriers for recurrent skin and soft tissue infections and treatment for impetigo. However, the indiscriminate use of mupirocin causes mupirocin resistance, associated with decolonization failure. The aim of the study was to investigate the epidemiology of mupirocin resistance and to identify clinical characteristics among children in a single center. Methods: From January 2011 to October 2020, we retrospectively analyzed the epidemiology of antibiotic resistance and clinical characteristics of pediatric patients under 19 years old in whom S. aureus was firstly isolated at any body site. Results: Of the 3, 414 S. aureus isolates, 46% (1569/3414) were methicillin-resistant, and 20.3% (692/3414) were mupirocin resistant. Among MRSA, Mupirocin-resistant (MupR) was 22.6% (354/1569), and among methicillin-sensitive S. aureus (MSSA), MupR was 18.3% (338/1845) ( P < 0.001). The median age of MupR MRSA patients was 0.14 years (interquartile range 0.04-0.79), and the median age of MupR MSSA patients was 5.0 years (interquartile range 2.0-8.1) ( P =0.000). Of 692 MupR S. aureus, 94.2% (652/692) were mainly detected in the skin. MupR MRSA was most frequently isolated in the neonatal intensive care unit (40.1%, 142/354), but MupR MSSA was most frequently isolated in the outpatient setting (81.4%, 275/338) ( P < 0.001). Of these, 43% (119/275) patients wereAbstract: Background: Mupirocin has been recommended for decolonization in methicillin-resistant Staphylococcus aureus (MRSA) carriers for recurrent skin and soft tissue infections and treatment for impetigo. However, the indiscriminate use of mupirocin causes mupirocin resistance, associated with decolonization failure. The aim of the study was to investigate the epidemiology of mupirocin resistance and to identify clinical characteristics among children in a single center. Methods: From January 2011 to October 2020, we retrospectively analyzed the epidemiology of antibiotic resistance and clinical characteristics of pediatric patients under 19 years old in whom S. aureus was firstly isolated at any body site. Results: Of the 3, 414 S. aureus isolates, 46% (1569/3414) were methicillin-resistant, and 20.3% (692/3414) were mupirocin resistant. Among MRSA, Mupirocin-resistant (MupR) was 22.6% (354/1569), and among methicillin-sensitive S. aureus (MSSA), MupR was 18.3% (338/1845) ( P < 0.001). The median age of MupR MRSA patients was 0.14 years (interquartile range 0.04-0.79), and the median age of MupR MSSA patients was 5.0 years (interquartile range 2.0-8.1) ( P =0.000). Of 692 MupR S. aureus, 94.2% (652/692) were mainly detected in the skin. MupR MRSA was most frequently isolated in the neonatal intensive care unit (40.1%, 142/354), but MupR MSSA was most frequently isolated in the outpatient setting (81.4%, 275/338) ( P < 0.001). Of these, 43% (119/275) patients were diagnosed with atopic dermatitis. By age, mupR MRSA was the more commonly isolated in infants younger than one year (77.4%, 274/354), and MupR MSSA was more commonly isolated in children older than three years old (65.4%, 221/338) ( P < 0.001). The frequency of MupR MRSA and MSSA showed an increase in trend over time ( P < 0.001). Among other topical agents, 6.5% (102/1569) of MRSA was resistant to fusidic acid. Conclusion: As mupirocin resistance gradually increases, a test for mupirocin susceptibility should be performed before applying the skin lesions or decolonization for MRSA. In addition, clinicians should carefully prescribe mupirocin to prevent the development of MupR S. aureus. Disclosures: Yae-Jean Kim, MD, PhD, Janssen: Grant/Research Support|Korean Society of Pediatric Infectious Diseases: Grant/Research Support|Ministry of Trade, Industry and Energy: Grant/Research Support|MSD: Grant/Research Support. … (more)
- Is Part Of:
- Open forum infectious diseases. Volume 9:(2022)Supplement 2
- Journal:
- Open forum infectious diseases
- Issue:
- Volume 9:(2022)Supplement 2
- Issue Display:
- Volume 9, Issue 2 (2022)
- Year:
- 2022
- Volume:
- 9
- Issue:
- 2
- Issue Sort Value:
- 2022-0009-0002-0000
- Page Start:
- Page End:
- Publication Date:
- 2022-12-15
- Subjects:
- Communicable diseases -- Periodicals
Medical microbiology -- Periodicals
Infection -- Periodicals
616.9 - Journal URLs:
- http://ofid.oxfordjournals.org/ ↗
http://www.oxfordjournals.org/en/ ↗ - DOI:
- 10.1093/ofid/ofac492.1156 ↗
- Languages:
- English
- ISSNs:
- 2328-8957
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 25196.xml